15 October 2015 - The CADTH Canadian Drug Expert Committee has recommended that empagliflozin be listed for the treatment of patients with type 2 diabetes mellitus if certain clinical criteria and conditions are met.

For more details, go to: https://www.cadth.ca/sites/default/files/cdr/complete/sr0427_jardiance_oct-19-15.pdf